Takeda’s HyHub and HyHub Duo Devices Now Available in the U.S.

The recently U.S. Food and Drug Administration-approved HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older who are prescribed HYQVIA (immune globulin infusion [human], 10% with recombinant human hyaluronidase). The dedicated devices allow HYQVIA, a facilitated subcutaneous immune globulin (SCIG) infusion comprised of dual vial units (DVUs) of immune globulin and hyaluronidase, to be transferred from vials without using a needle or pooling bag in a home environment or clinical setting. 

HyHub and HyHub Duo reduce the number of steps required to prepare the IG and hyaluronidase of the HYQVIA infusion by up to half compared to infusing with a pooling bag, depending on the device and number of DVUs used. HyHub and HyHub Duo also reduce the ancillary supplies required to prepare the infusion and a dedicated carrier bag is available for convenience that enables limited mobility, such as moving from room to room.